Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...

Interested parties may access the conference call on August 12, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the ...

Lineage Cell Therapeutics (AMEX:LCTX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed ...

Lineage Cell Therapeutics, Inc. ((LCTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Lineage Cell Therapeutics Faces Mixed Sentiments Amidst Progress and Financial ...

According to a regulatory filing, as previously reported, in December 2021, Lineage Cell Therapeutics (LCTX) entered into a collaboration and license agreement with Genentech, Inc. and Roche (RHHBY) ...

Novel engineered iPS cell line to be evaluated by Lineage for potential development of cell transplant therapies for central nervous system diseases under collaboration initiated in early 2023 Lineage ...

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...

Russo Partners – Media Relations Nic Johnson or David Schull (Nic.johnson@russopartnersllc.com) (David.schull@russopartnersllc.com) (212) 845-4242 Source: Lineage Cell Therapeutics, Inc. The views and ...